drugset
drugset / Trial / NCT07491289

GS1-144 in Participants With Hepatic Impairment and Healthy Female

NCT07491289 ↗

Phase 1 Not yet recruiting 24 enrolled Changchun GeneScience Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

GS1-144 in Participants with Hepatic Impairment and Healthy Female

Timeline

Start
2026-04-20
Primary completion
2027-01-31
Completion
2027-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject GS1-144 Unknown 30 mg Oral

Indications

No indication recorded.